Latest FDA product-specific guidelines – Some questions… [Regulatives / Guidelines]

posted by nobody – 2017-07-19 12:56 (2463 d 02:43 ago) – Posting: # 17560
Views: 10,951

Hy everybody!

Had a quick glance at the latest FDA guidances/revisions and found some stuff I don't understand immediately:

- Aspirin+Omeprazole delayed release tablet: BE for ASS based on both, ASS and SS
- Aspirin ER capsule or Aspirin capsule (from 2015): BE based on ASS alone

Any obvious reason for this?

- Tiopronin tablet (Shkreli compound): Only 1 study in fasted state

Are there more compounds not requiring fed state study?

- Metoprolol tartrate: BCS-biowaiver requires data other than "peer-reviewed articles"

Plausible to me, own experimental data on solubility might be required. Has anybody identified a PAR with successful BCS-biowiaver? :-D

- Propafenon: Highly variable.

Is CYP2D6 substrate, poor/ultrarapid metabolizers might be the reason for high variability? Why not pheno/genotype the volunteers for BE-trial, to minimize variability?

...just asking ;-)

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
22,984 posts in 4,822 threads, 1,651 registered users;
52 visitors (0 registered, 52 guests [including 4 identified bots]).
Forum time: 15:40 CEST (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5